Needham raised the firm’s price target on TransMedics (TMDX) to $166 from $148 and keeps a Buy rating on the shares. The SRTR – Scientific Registry of Transplant Recipients – data for October 2025 indicates that the company’s transplant volumes were likely above the average monthly rate in Q3, and based on the SRTR data, the firm estimates that TransMedics had a transplant volume of 460 in October vs. its estimated average monthly transplant volume of 394 in Q3, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics Group: Positive Trends in Flight and Organ Transplant Volumes Justify Buy Rating
- Positive Market Trends and TransMedics Aviation Drive Buy Rating for TransMedics Group
- TransMedics price target raised to $135 from $123 at Morgan Stanley
- TransMedics rises 10.4%
- TransMedics Group’s Earnings Call Highlights Robust Growth and Strategic Expansion